Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy

Che-Ping Cheng1, Heng-Jie Cheng, Carol Cunningham

  • 1Cardiology Section, Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, USA. ccheng@wfubmc.edu

Circulation
|July 13, 2006
PubMed
Abstract

Insights

Alcohol consumption activates the renin-angiotensin system (RAS), leading to alcoholic cardiomyopathy. Blocking the angiotensin II (Ang II) type 1 receptor (AT1) with irbesartan prevents this cardiac dysfunction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Toxicology

Background:

  • Alcoholic cardiomyopathy is a potential consequence of chronic alcohol consumption.
  • The renin-angiotensin system (RAS) may play a role in the development of alcoholic cardiomyopathy.

Purpose of the Study:

  • To investigate the effect of angiotensin II (Ang II) type 1 receptor (AT1) blockade on alcoholic cardiomyopathy development.
  • To evaluate the impact of irbesartan on cardiac function and RAS activation in alcohol-fed dogs.

Main Methods:

  • Instrumented dogs were divided into three groups: alcohol, alcohol plus irbesartan, and control.
  • Left ventricular (LV) and cardiomyocyte function, along with RAS markers, were monitored over six months.
  • Measurements included LV contractility, myocyte shortening and relengthening, and calcium transients.

Main Results:

  • Alcohol ingestion led to sustained RAS activation, evidenced by increased Ang II, renin activity, and AT1 receptor expression.
  • Cardiac dysfunction manifested as decreased LV contractility, impaired myocyte function, and reduced calcium handling.
  • Irbesartan treatment prevented alcohol-induced cardiac dysfunction and suppressed RAS activation.

Conclusions:

  • Chronic alcohol consumption activates the RAS, causing progressive cardiac dysfunction.
  • AT1 receptor blockade effectively prevents the development of alcoholic cardiomyopathy.

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...